Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study

Rishikesh Mankidy, Pearson WK Ahiahonu, Hong Ma, Dushmanthi Jayasinghe, Shawn A Ritchie, Mohamed A Khan, Khine K Su-Myat, Paul L Wood and Dayan B Goodenowe*

Abstract

Background: Disrupted cholesterol regulation leading to increased circulating and membrane cholesterol levels is implicated in many age-related chronic diseases such as cardiovascular disease (CVD), Alzheimer’s disease (AD), and cancer. *In vitro* and *ex vivo* cellular plasmalogen deficiency models have been shown to exhibit impaired intra- and extra-cellular processing of cholesterol. Furthermore, depleted brain plasmalogens have been implicated in AD and serum plasmalogen deficiencies have been linked to AD, CVD, and cancer.

Results: Using plasmalogen deficient (NRel-4) and plasmalogen sufficient (HEK293) cells we investigated the effect of species-dependent plasmalogen restoration/augmentation on membrane cholesterol processing. The results of these studies indicate that the esterification of cholesterol is dependent upon the amount of polyunsaturated fatty acid (PUFA)-containing ethanolamine plasmalogen (PlsEtn) present in the membrane. We further elucidate that the concentration-dependent increase in esterified cholesterol observed with PUFA-PlsEtn was due to a concentration-dependent increase in sterol-O-acyltransferase-1 (SOAT1) levels, an observation not reproduced by 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition.

Conclusion: The present study describes a novel mechanism of cholesterol regulation that is consistent with clinical and epidemiological studies of cholesterol, aging and disease. Specifically, the present study describes how selective membrane PUFA-PlsEtn enhancement can be achieved using 1-alkyl-2-PUFA glycerols and through this action reduce levels of total and free cholesterol in cells.

Background

A breakdown in cholesterol homeostasis has adverse effects at the cellular level, as well as in the context of the organism. Altered cholesterol content in cells affects membrane fluidity, which has drastic effects on cellular function, signal transduction, and intercellular communication events [1,2]. Elevated levels of circulating cholesterol have been linked with the formation of atherosclerotic plaques, and is a risk factor for cerebrovascular lesions and coronary heart disease [3,4]. Apolipoprotein E4 (ApoE4), a vehicle for cholesterol transport, is a major risk factor for sporadic Alzheimer’s disease (AD), demonstrating a link between cholesterol and cognition [5]. Increase in cholesterol in tumor tissue is a common underlying feature in a number of cancers; safety data from randomized clinical trials of cholesterol lowering statins demonstrated lower incidences of melanoma, colorectal, breast and prostate cancers, reviewed by Hager and coworkers [6].

Cholesterol exists in two mutually exclusive pools in the body separated by the blood brain barrier. Within each pool it can be found either in a free (unesterified) state, or it can exist as esters. Brain cholesterol is synthesized *de novo*, and accounts for 25% of the total body cholesterol, wherein it exists primarily as free cholesterol in myelin and the plasma membranes of glial cells and neurons [7,8]. The remaining cholesterol is accounted for in tissues and in circulation. The plasma membrane of cells is predominantly composed of unesterified cholesterol, which is enriched in microdomains called lipid rafts, key structural requirements for signal transduction. Circulating cholesterol on the other hand is coupled with lipoproteins (chylomicrons, VLDL, LDL and HDL). Chylomicrons, VLDL and LDL serve as vehicles for the movement of proteins.
dietary cholesterol to the liver for removal from circulation. HDL, synthesized by the liver and intestine, is the vehicle for the transport of tissue cholesterol to the liver for excretion, a process called reverse cholesterol transport (reviewed by Martins and coworkers) [9].

Plasmalogens are a class of glycerophospholipids characterized by a vinyl-ether linkage at the sn-1 position and an acyl linkage at the sn-2 position of the glycerol backbone. Besides contributing to membrane structural integrity, plasmalogens are involved in multiple cellular functions such as vesicle formation and membrane fusion [10-12], ion transport [13-15] and generation of secondary signal mediators such as platelet activating factor (PAF) [16,17]. Presence of the vinyl ether bond imparts antioxidant properties to these molecules which mitigates free radical based cellular damage [18-21].

The multitude of functions attributed to this class of molecules implicates it in a number of human disorders ranging from peroxisomal disorders such as Zellweger syndrome, rhizomelic chondrodysplasia punctata (RCDP), infantile Refsum disease and cholesterol storage disorders such as Neiman-Pick type C disease to Down's syndrome and Alzheimer's disease [22-28]; Ethanolamine plasmalogen depletion has been observed in post-mortem brains of AD subjects [29,30] and in the serum of subjects suffering from AD [31], cardiovascular disease [32], and cancer [33].

Studies have shown that brain and circulating plasmalogens negatively correlate with age [34-36]. Additionally, plasmalogens have been linked with altered cholesterol processing [37-39]; a plasmalogen-deficient cell exhibits lower esterified cholesterol and a lower rate of HDL-mediated cholesterol efflux. Meaba and coworkers recently showed a link between plasmalogens and Apo A1 and A2, the major components of HDL [35].

These observations prompted us to investigate the relationship between membrane plasmalogen level and cholesterol regulation using both plasmalogen deficient (NRel-4) and sufficient (HEK293) cell lines. A novel species-specific plasmalogen restorative/augmentation approach was applied to both cell types and the resulting effect on cholesterol (total, esterified, and free) and sterol-O-acyltransferase-1 (SOAT1 encodes acyl-coenzyme A:cholesterol acyl transferase, ACAT, a critical membrane bound cholesterol processing enzyme), levels ascertained. This report identifies the use of plasmalogens in achieving cholesterol homeostasis as an alternative to statin therapy.

**Materials and Methods**

**Syntheses of Compounds for Structure Activity Relationship Study**

The compounds used for this structure activity relationship study were synthesized from readily available starting materials as shown in the synthetic scheme (Figure 1) and in Table 1.

**General Methods**

All chemicals and solvents were purchased from Sigma-Aldrich Canada Ltd., Oakville, ON., VWR Canada and Nu-Chek Prep., Elysian, MN. All solvents used were anhydrous. Analytical thin layer chromatography (TLC) was carried out on precoated silica gel TLC aluminum sheets (EM science, Kieselgel 60 F254, 5 × 2 cm × 0.2 mm). Compounds were visualized under UV light (254/366 nm) or placed in iodine vapor tank and by dipping the plates in a 5% aqueous (w/v) phosphomolybdic acid solution containing 1% (w/v) ceric sulfate and 4% (v/v) H2SO4, followed by heating. Flash column chromatography was carried out using silica gel, Merck grade 60, mesh size 230-400, 60 Å. NMR spectra were recorded on Bruker Avance spectrometers; for 1H (500 MHz), δ values were referenced to CDCl3 (CHCl3 at 7.24 ppm) and for 13C NMR (125.8 MHz) referenced to CDCl3 (77.23 ppm). Coupling constants (J) are reported to the nearest 0.5 Hz. High resolution mass spectral data were obtained on Bruker Apex 7T Fourier transform ion cyclotron resonance mass spectrometer (FT-ICRMS) with atmospheric pressure chemical ionization in the positive mode (HRAPCI-MS). MS/MS data collected using QStar XL TOF mass spectrometer with atmospheric pressure chemical ionization (APCI) source in the positive mode and collision energy of 20 and 35 V. Fourier transform infra-red (FTIR) spectra were recorded on Bio-Rad FTS-40 spectrometer using the diffuse reflectance method on samples dispersed in KBr. Refer synthetic scheme (Figure 1) and Table 1 for details of compounds synthesized.
General procedure for synthesis of C11-13
To sodium hydride (1.85 g, 60% dispersed in mineral oil) under argon was added anhydrous N, N-dimethylformamide (DMF, 10 ml) at room temperature (RT). Solketal (16.7 mmol) in 10 ml anhydrous DMF was then added dropwise with constant stirring. 1-Bromohexadecane, 1-bromooctadecane or octadec-9-enylmethane sulphonate (16.7 mmol) [40,41] dissolved in anhydrous DMF (10 ml) was then added to the reaction mixture dropwise and stirred for 48 hours. The reaction mixture was poured into cold ice water (100 ml) and extracted with hexane (100 ml, 3×). After drying over anhydrous Na2SO4 and removal of solvent, the crude product was treated with 10% HCl solution (40 ml) and refluxed at 120°C for 30 min. The reaction mixture was then kept at RT for 24 hours. The off white lumps and the mother liquor was extracted with diethylether (100 ml, 3×) washed successively with saturated aqueous NaHCO3 (100 ml) and water (100 ml), dried over anhydrous Na2SO4 and the solvent removed under reduced pressure to obtain the products C11-13. Satisfactory spectral and analytical data were obtained [42].

Table 1: List of compounds synthesized for the SAR study.

| Compound | sn-1 (R1) | sn-2 (R2) | sn-3 |
|----------|-----------|-----------|------|
| 1 cis-(±)-2-O-docosahexaenoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | DHA | OH |
| 2 cis-(±)-2-O-docosahexaenoyl-1-O-octadecylglycerol | 18:0 (alkyl) | DHA | OH |
| 3 cis-(±)-2-O-docosahexaenoyl-1-O-octadec-9-enylglycerol | 18:1 (alkyl) | DHA | OH |
| 4 cis-(±)-2-O-docosahexaenoyl-1-O-palmitoylglycerol | 16:0 (acyl) | DHA | OH |
| 5 cis-(±)-2-O-docosahexaenoyl-1-O-stearoylglycerol | 18:0 (acyl) | DHA | OH |
| 6 cis-(±)-2-O-stearoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | 18:0 | OH |
| 7 cis-(±)-2-O-oleoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | 18:1 | OH |
| 8 cis-(±)-2-O-linoleoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | 18:2 | OH |
| 9 cis-(±)-2-O-α-linolenoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | 18:3 | OH |
| 10 cis-(±)-2-O-arachidonoyl-1-O-hexadecylglycerol | 16:0 (alkyl) | 20:4 | OH |

All molecules had a glycerol backbone, and differed in the sn-1 and sn-2 fatty acid acids. The sn-1 fatty acid was linked to glycerol either by an alkyl or acyl linkage.

General procedure for synthesis of C14-18
To a mixture of each of compounds C11-13 (1.63 mmol), monopalmitin and monostearin (1.63 mmol) was dissolved separately in anhydrous DMF (2.00 ml) followed by the addition of imidazole (3.72 mmol) and tert-butyl dimethylsilyl chloride (1.88 mmol). The reaction mixture was stirred at RT for 24 hours, poured into water (100 ml) and extracted with diethyl ether (100 ml, 3×). After removal of solvent, the crude product was chromatographed on silica gel using CH2Cl2-MeOH to obtain the products [43].

General procedure for synthesis of C19-28
To a mixture of each of C14-18 (0.578 mmol), anhydrous pyridine (0.35 ml), catalytic amount of dimethylaminopyridine (0.100 mmol) and toluene (5 ml) was added the appropriate acyl chloride like (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl chloride (0.576 mmol) dropwise under argon and stirred at RT for 48 hours. The reaction mixture was poured into water (100 ml), extracted with diethyl ether (100 ml, 3×), washed successively with 0.25 M H2SO4 solution (100 ml), saturated aqueous NaHCO3 (100 ml) and water (100 ml). After drying over anhydrous Na2SO4 and removal of solvent, the crude product was subjected to chromatography on silica gel using CH2Cl2-MeOH to obtain the products.

General procedure for synthesis of C1-10
To a mixture of each of C19-28 (0.272 mmol) and THF (2 ml) was added imidazole (0.942 mmol) and 0.80 ml of 1.0
M TBAF in THF dropwise at -20°C and kept at this temperature for 24 hours with constant stirring. The reaction mixture was then passed through a plug of silica gel and eluted with cold diethyl ether (10 ml - 20°C). After removal of solvent, the crude products were chromatographed on silica gel using hexane - ethyl acetate mixtures to obtain the products [44,45].

**Spectral data for cis-(±)-2-O-Docosahexaenoyl-1-O-hexadecylglycerol (C1)**

Obtained from C19, as light yellow oil; 144.6 mg (67%);
TLC: \( R_f = 0.65 \) (CH\(_2\)Cl\(_2\):MeOH, 95:5 v/v); \(^1\)H NMR (CDCl\(_3\)): \( \delta \) in ppm 0.86 (3H, t, \( J = 7.0 \) Hz), 0.95 (3H, \( t, J = 7.0 \) Hz), 1.23-1.27 (24H, m), 1.52-1.56 (4H, m), 2.06 (2H, m), 2.17 (1H, br s), 2.38-2.41 (4H, m), 2.79-2.82 (10H, m), 3.38-3.47 (2H, m), 3.56-3.63 (2H, m), 3.76-3.79 (2H, m), 4.98 (1H, quintet, \( J = 5.0 \) Hz), 5.33-5.38 (12H, m); \(^{13}\)C NMR (CDCl\(_3\)): \( \delta \) in ppm 14.3, 14.4, 20.7, 22.7, 23.0, 25.8, 25.9, 26.3, 29.6, 29.7, 29.8 (3), 29.9, 32.1, 34.5, 63.2, 70.1, 72.1, 73.3, 127.2, 128.0, 128.1, 128.2, 128.3 (2), 128.5 (3), 128.8, 129.6, 132.3, 173.1; FT-IR (cm \(^{-1}\)) 3397 (br), 2931, 2852, 1722; HRAPCI-MS m/z: 627.5353 ([M + H\(^+\)], 80%), 609 (20%), 385 (40%), 329 (15%), 311 (100%), 293 (90%), 269 (35%), 75 (70%).

**Spectral data for cis-(±)-2-O-Docosahexaenoyl-1-O-octadecylglycerol (C2)**

Obtained from C20, as light yellow oil; 75.2 mg (66.3%);
TLC: \( R_f = 0.80 \) (CH\(_2\)Cl\(_2\):MeOH, 95:5 v/v); \(^1\)H NMR (CDCl\(_3\)): \( \delta \) in ppm 0.86 (3H, \( t, J = 7.0 \) Hz), 0.95 (3H, \( t, J = 7.0 \) Hz), 1.23-1.27 (28H, m), 1.50-1.56 (4H, m), 2.05 (2H, m), 2.19 (1H, br s), 2.37-2.42 (4H, m), 2.78-2.83 (10H, m), 3.38-3.46 (2H, m), 3.55-3.63 (2H, m), 3.76-3.79 (2H, m), 4.98 (1H, quintet, \( J = 5.0 \) Hz), 5.33-5.38 (12H, m); \(^{13}\)C NMR (CDCl\(_3\)): \( \delta \) in ppm 14.3, 14.4, 20.7, 22.7, 23.0, 25.8, 25.9, 26.3, 29.6, 29.7, 29.8 (3), 29.9, 32.1, 34.5, 63.2, 70.1, 72.1, 73.3, 127.2, 128.0, 128.1, 128.2, 128.3 (2), 128.5 (3), 128.8, 129.6, 132.3, 173.1; FT-IR (cm \(^{-1}\)) 3385 (br), 2917, 2852, 1722; HRAPCI-MS m/z: 627.5353 ([M + H\(^+\)], 80%), 609 (20%), 385 (40%), 329 (15%), 311 (100%), 293 (90%), 269 (35%), 75 (70%).

**Q-TRAP analysis**

The plasmalog-en-deficient CHO cell line (NRel-4) was used to assay the efficacy of test compounds C1-10 in plasmalogen restoration. CHO (wild type) or NRel-4 (plasmalogen deficient) cells were seeded in DMEM/F-12 medium (10% FBS) on a 10 cm dish the day before the experiment. The following day, the media was replaced with fresh media containing the test compound or the solvent ethanol (0.1% V/V) as a control [46]. Cells were cultured for 72 hours at 37°C, 5% CO\(_2\), after which they were harvested using Versene/TrypLE express (Gibco Life Technology, Rockville, MD). The cell pellet was washed with phosphate buffered saline (PBS, pH 7.4), and the phospholipids were extracted and analyzed using a linear ion-trap mass spectrometer coupled to a LC system as described [31].

**Cholesterol Assay**

Human embryonic kidney 293 (HEK293) cells and CHO/NRel-4 cells were seeded the day before the treatment. The following day, the cells were treated with the test compounds C1-10 or with ethanol as the control. Concentrations used for pravastatin, clofibrate, and troglitazone treatments were as described [47-49]. Cells were harvested after 48 hours using Versene:TrypLE express cocktail, washed with PBS. Lipids were extracted with chloroform containing 1% Triton X-100. The organic fraction was recovered and dried under a stream of nitrogen. The dried lipids were resuspended in cholesterol reaction buffer (Biovision, Mountain View, CA), and the total, free and esterified fractions of cholesterol were quantified using the cholesterol quantification kit (Biovision, Mountain View, CA) as per the manufacturer’s recommendations. Cholesterol was reported as μg/million cells.
Figure 2 Relative ethanolamine plasmalogens in DHAPAT-deficient cells (A). Plasmalogen content of CHO (C_V) and NRel-4 (N_V) cell lines. Values are an average of three independent experiments; error bars represent standard deviation. All transitions measured in NRel-4 cells were significantly different from control cells (p < 0.05). Cholesterol profile of DHAPAT-deficient cells (B). Values are an average of independent experiments; error bars represent standard deviation. Total, free and esterified cholesterol of N_V is significantly different from C_V (p < 0.05).
Immunoblotting and Immunoprecipitation

HEK293 cells were treated as described in the amyloid assay. The cell pellet was washed in PBS and lysed in RIPA buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MI). Protein in the cell lysate was quantified using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). The following antibodies were used for western analyses: SOAT1 (Santa Cruz Biotechnology Inc., CA) and β-actin (Sigma, St. Louis, MI). Band intensities were calculated using ImageJ (National Institutes of Health).

Statistical analysis

Statistical Analysis of the data was performed using Microsoft Office Excel 2007 and JMP version 8. Multiple comparison Dunnett’s tests were applied to analyze the differences between the treatments and the control.

Results

The Effect of Plasmalogen Deficiency on Membrane Cholesterol Composition

Membrane plasmalogen levels of NRel-4 cells, lacking dihydroxyacetone phosphate acyl transferase (DHAPAT), an obligate enzyme in the plasmalogen biosynthesis pathway [50,51], were less than 10% of wild-type CHO cells (Table 2 and Figure 2A) as assessed through the relative quantification of five common palmitoyl ether ethanolamine plasmalogens (PlsEtn). The cell membranes of NRel-4 cells also contained nearly 2-fold more free cholesterol and 4-fold less esterified cholesterol in their cell membranes. To determine whether this effect was due to a general decrease in membrane PlsEtn composition or to decreased levels of esterified cholesterol (Figure 8C).

The Effect of Plasmalogen Precursor sn-1 and sn-2 Substituents on Plasmalogen Composition in CHO and NRel-4 Cells

Using wild CHO and NRel-4 cells, side chain-specific PlsEtn and phosphatidylethanolamine (PtdEtn) precursors (Table 1) were evaluated for their abilities to augment cellular plasmalogen levels in control (CHO) and PlsEtn-deficient (NRel-4) cells. These alkylacylglycerol ethers bypass the requirement for peroxisomes in the synthesis of plasmalogens (Figure 3). The following observations were made:

1. Maintaining the free alcohol at sn-3 and DHA at sn-2. PlsEtn precursors C1-3 with differing long chain ether substitutions at sn-1 revealed that these precursor compounds either partially or fully restored all ethanolamine plasmalogens with the same sn-1 alkyl ether but had no effect on PlsEtn with different sn-1 compositions (Figure 4). For example, treatment with a palmitoyl PlsEtn precursor (C1) restored the downstream pool of 16:0 ethanolamine plasmalogens with no effect on the 18:0 and 18:1 PlsEtn pools. Such side chain-specific restoration indicates that no rearrangement of the sn-1 moiety (O-alkyl linkage) occurs, while the sn-2 moiety is able to undergo deacylation and subsequent reacylation with other fatty acid residues.

2. Similarly, compounds C6-C10 (16:0 at sn-1 but differing at the sn-2 substituent) significantly elevate the 16:0 pool, with no effect on the 18:0 and 18:1 pools of PlsEtn (Figure 4).

3. Distribution of PlsEtn within a pool (16:0, 18:0 or 18:1) depends on the fatty acid at sn-1 position. C1 and C3 showed maximum restoration of the PlsEtn directly downstream in the pathway (16:0/22:6 PlsEtn and 18:1/22:6 PlsEtn respectively). C2 on the other hand significantly augments all PlsEtns in the 18:0 pool (Figure 5).

4. Comparison of compounds C1, C6-10, revealed that whereas DHA containing precursors can partially or fully restore all other sn-2 PlsEtns, non-DHA containing precursors cannot completely restore DHA-PlsEtn (Figure 6A).

5. DHA-PtdEtn precursors (C4 and C5) cannot restore DHA-PlsEtn deficiencies (Figure 6B).

6. PlsEtn precursors with DHA at sn-2 concentration-dependently increase DHA-PlsEtn in both DHAPAT deficient cells (NRel-4) and wild-type cells (CHO) (Figure 7A). However, with respect to total plasmalogen content, only the deficient cell line showed an increase; no augmentation in total plasmalogen content was observed in wild-type CHO cells (Figure 7B).

The Effect of Plasmalogen Precursor Structure on Membrane Cholesterol Composition

As demonstrated above, plasmalogen deficient cells have higher content of free cholesterol and lower amounts of esterified cholesterol in their cell membranes. To determine whether this effect was due to a general decrease in membrane PlsEtn composition or to decreased levels of specific PlsEtn, membrane PlsEtn levels in PlsEtn depleted cells (NRel-4) were selectively restored as described above and the corresponding effect on membrane cholesterol composition ascertained. The key observations were:

1. PtdEtn precursors (C4 and C5) had no effect, while PlsEtn precursors with <3 unsaturations (C7 and C8) had a mild effect on membrane cholesterol composition (Figure 8).

2. PlsEtn precursors with 3 or more unsaturations (C1, C9 and C10) had a more profound effect on reducing free cholesterol (Figure 8B) and increasing esterified cholesterol (Figure 8C).

The effect of plasmalogen precursors and other compounds on membrane cholesterol composition was further studied in PlsEtn normal human HEK293 cells (Figure 9). The key observations were:
1. PlsEtn precursor C1 exhibited a concentration-dependent decrease in free cholesterol (47% at 20 μM) (Figure 9B) and a reciprocal increase in the esterified fraction of cholesterol (31% at 20 μM) (Figure 9C).

2. PtdEtn precursors (C4 and C5) had no effect on free cholesterol and resulted in slight decreases in esterified cholesterol.

3. PlsEtn precursors with sn-2 substituents containing < 3 unsaturations (C6, C7 and C8) either elevated or had no effect on free cholesterol.

4. PlsEtn precursors with sn-2 substituents containing 3 or more unsaturations either reduced free cholesterol (C1 and C9) and/or increased esterified cholesterol (C1 and C10).

#### Table 2: Ethanolamine plasmalogen distribution in cell lines

| Absolute Signal       | CHO       | NRel-4    | HEK293    |
|-----------------------|-----------|-----------|-----------|
| PlsEtn 16:0/18:1      | 4.935 (11.6) | 0.385 (9.2) | 5.860 (13.7) |
| PlsEtn 16:0/18:2      | 4.650 (10.9) | 0.405 (9.7) | 0.944 (2.2) |
| PlsEtn 16:0/18:3      | 0.069 (0.2)  | 0.008 (0.2) | 0.127 (0.3) |
| PlsEtn 16:0/20:4      | 5.900 (13.8) | 0.997 (23.9) | 9.053 (21.1) |
| PlsEtn 16:0/22:6      | 0.442 (1.0)  | 0.093 (2.2) | 2.737 (6.4) |
| PlsEtn 18:0/18:1      | 3.580 (8.4)  | 0.273 (6.5) | 2.840 (6.6) |
| PlsEtn 18:0/18:2      | 4.155 (9.7)  | 0.312 (7.5) | 0.556 (1.3) |
| PlsEtn 18:0/18:3      | 0.059 (0.1)  | 0.004 (0.1) | 0.072 (0.2) |
| PlsEtn 18:0/20:4      | 6.300 (14.8) | 0.660 (15.8) | 5.780 (13.5) |
| PlsEtn 18:0/22:6      | 0.491 (1.1)  | 0.104 (2.5) | 1.787 (4.2) |
| PlsEtn 18:1/18:1      | 3.805 (8.9)  | 0.213 (5.1) | 4.227 (9.9) |
| PlsEtn 18:1/18:2      | 3.390 (7.9)  | 0.185 (4.4) | 0.623 (1.5) |
| PlsEtn 18:1/18:3      | 0.065 (0.2)  | 0.003 (0.1) | 0.078 (0.2) |
| PlsEtn 18:1/20:4      | 4.390 (10.3) | 0.485 (11.6) | 6.170 (14.4) |
| PlsEtn 18:1/22:6      | 0.431 (1.0)  | 0.048 (1.1) | 2.0167 (4.7) |
| **Total PlsEtn Sum**  | **42.660 (100)** | **4.173 (100)** | **42.870 (100)** |

Absolute signal intensities of the various plasmalogen species measured in CHO, NRel-4 cells, and HEK293 cell lines. Values in brackets are the percentage of total PlsEtn sum.
**Peroxisome Metabolism**

Dihydroxyacetone phosphate (DHAP)

- DHAP-AT
- 1-acyl DHAP
  - alkyl-DHAP synthase
- 1-alkyl-DHAP
  - ketone Reductase
- 1-alkyl-G3P

- Translocation to the ER

**ER Metabolism**

1-alkyl-G3P

- 1-alkyl-2-acyl-G3P
  - phosphohydrolase
- 1-alkyl-2-acyl-glycerol
  - CDP-ethanolamine
- 1-alkyl-2-acyl-glycerophospho ethanolamine
  - desaturase
- 1-alkenyl-2-acyl-GPE (PisEtn)

**Figure 3** Plasmalogen biosynthetic pathway showing therapeutic intervention.
5. Free DHA had a slight impact on free cholesterol (14% reduction) compared to control, while it exhibited a 24% increase in the esterified cholesterol fraction at the 20 μM concentration.

6. Pravastatin treatments were most potent in reducing free cholesterol at 10 μM concentration (24% reduction compared to control, p = 0.01), while the 100 μM concentration did not result in a further reduction of free cholesterol. The changes observed in the esterified cholesterol were not significant.

7. Treatments with PPARα (clofibrate; 100 and 200 μM) and PPARγ (troglitazone; 1 and 10 μM) agonists had no impact on the cholesterol profile of HEK293 cells at the concentrations tested.

**Effect of PUFA-PlsEtn enhancement and HMG-CoA inhibition on cellular SOAT1 levels**

The effects of the potent cholesterol esterification enhancing/total cholesterol lowering PlsEtn precursor, C1, and of the potent HMG-CoA reductase inhibiting/total cholesterol lowering statin, pravastatin, on the basal levels of cholesterol processing enzyme SOAT1 was determined. The maximum cholesterol-lowering concentration of C1, resulted in a 50% elevation of SOAT1 levels (calculated using ImageJ software), whereas the maximum cholesterol-lowering concentration of pravastatin had no effect on SOAT1 levels (Figure 10).

**Discussion**

Plasmalogens are major structural and functional lipids of the cell. The discovery of this class of molecules was made originally in myelin by Feulgen and Voit in 1924 [52], but the accurate structure of plasmalogens was deduced only several years later [53,54]. The biological function of plasmalogens, and their implication in diseases remained elusive for a number of years until a recent spike in interest in these lipids. In this report we discuss the interplay between plasmalogens and cholesterol, and investigate a plasmalogen restoration approach *in vitro*.

The plasma membrane is the major storage location of free cholesterol in that 80 to 95% of total cellular cholesterol is found there, dependent upon cell type [55-58]. Excess cholesterol is transported out of peripheral cells via HDL proteins following esterification in the membrane and back to the liver via a process called reverse transport [59,60]. Within the cell, cholesterol is transported from the plasma membrane to other cellular compartments via LDL after esterification within the membrane [61,62].

PlsEtn deficient cells have been previously shown to have impaired HDL-mediated cholesterol efflux [38] and impaired intracellular LDL-mediated transport [39]. In both of these studies normal functionality was observed by either PlsEtn precursor treatment [38] or re-instate-
Figure 5 Sn-2 rearrangement following C1, C2, C3, C6-10 treatment of NRel-4 (N_V) cells. Relative distribution of sn-2 fatty acids within each plasmalogen pool following treatments as above is displayed. All PlsEtn measurements are reported relative to the control CHO cells (C_V). Results are an average of three independent experiments. Error bars represent standard deviation.
ment of the PlsEt biosynthesis pathway [39]. Our data is consistent with these studies in that plasmalogen deficient cells were observed to have reduced levels of esterified cholesterol and increased levels of free and total cholesterol (Figure 8) in the membrane. We have expanded upon these studies by investigating in greater detail the effect of membrane PlsEt speciation on membrane cholesterol esterification. By using a PlsEt deficient cell model (NRel-4) we selectively restored different PlsEt species by treating the cells with different 1-alkyl-2-acyl glycerols (PlsEt precursors). A comparison between precursors C1, C2, and C3 (which differ only in

![Figure 6 Comparison of sn-2 fatty acid substitution (A) and sn-1 bond type (B) on total DHA PlsEt levels in NRel-4 cells.](image)
the sn-1 fatty acid) revealed that the sn-1 substituent affected rearrangement at sn-2 position (Figure 5), and hence the downstream restoration of plasmalogens. This effect could be explained on the basis of stability of the compounds. The DHA moiety in C2 is possibly more labile (compared with C1 and C3) due to the steric hindrance caused by 18:0 fatty acid at sn-1 position.

These structure activity relationships revealed that changes in membrane PUFA-PlsEtn levels are principally responsible for the observed cholesterol effect (Figure 8) and that restoration of membrane PUFA-PlsEtn levels restores cholesterol homeostasis. The effect of membrane PlsEtn modification using 1-alkyl-2-acyl glycerol PlsEtn precursors on membrane cholesterol homeostasis was further investigated using a human cell line (HEK293) with normal PlsEtn biosynthetic machinery. PlsEtn precursor C1 concentration-dependently increased membrane esterified cholesterol (Figure 9C) and decreased free and total cholesterol (Figure 9A, B). Additionally, PUFA-PlsEtn precursors were observed to be approximately twice as effective as statins at lowering cholesterol levels. Treatment of the cells with DHA showed a slight, yet significant reduction in free cholesterol in agreement with the literature [63]. These results, in combination with the detailed study of Munn and coworkers [39] strongly indicate that PUFA-PlsEtn precursors reduce membrane cholesterol levels via increased membrane cholesterol esterification and transport. While it is true
Figure 8 Cholesterol profile of CHO/NRel-4 cells. Cholesterol profile of NRel-4 cells following 48 hour treatments with PlsEtn precursors (C1, C6-10) and PtdEtn precursors (C4, C5) compared to control CHO cells. A: total cholesterol; B: free cholesterol; C: esterified cholesterol. Cholesterol is reported as μg per million cells. Results are an average of three independent experiments. Asterisk represents values that are significantly different from those observed in DHAPAT-deficient NRel-4 cells (p < 0.05).
Figure 9 Cholesterol profile of HEK293 cells treated for 48 hr with plasmalogen precursors. Cholesterol (total, free and esterified) content is reported as μg/million cells, and is an average of two independent experiments. Error bars indicate standard deviation. Asterisk indicates significantly lower total or free cholesterol, or significantly higher esterified cholesterol compared with control.
that treatment of cells with PUFA-PlsEtn results in greater esterification of cholesterol, it is not expected to result in conditions similar to those in cholesterol ester storage diseases, Cholesterol storage disease is caused by lesions in the gene encoding lysosomal acid lipase. In conditions where the lysosomal enzyme is intact, it is expected that the cholesterol esters would be efficiently packed into high density lipoprotein complexes to form HDL-cholesterol for reverse cholesterol transport.

The observed increase in cholesterol esterification is suggested to be due to elevated SOAT1, an enzyme expressed in liver cells and macrophages which is involved in cholesterol homeostasis (Figure 10). These observations explain the increase in esterified cholesterol and an elevated rate of HDL-mediated cholesterol efflux reported by others [38,39]. These effects could not be reproduced by either PPAR agonists or by HMG-CoA reductase antagonists indicating that membrane PUFA-PlsEtn enhancement is a novel mechanism for lowering membrane cholesterol levels.

It is prudent to note that ACAT inhibition was thought to be a promising pharmaceutical target for controlling hypercholesterolemia. Several ACAT inhibitors entered clinical trials, only to emerge with disappointing results. Avasimibe and pactimibe treatment did not hamper the progression of coronary atherosclerosis [64,65]. On the contrary, in both trials the ACAT inhibitors resulted in a significant elevation in LDL cholesterol over the placebo arm, prompting an early termination of the trials. Additionally, in pactimibe trials, the treatment groups showed a significant increase in atheroma volume in the coronary artery [66], and significant increase in carotid intima-media thickness compared to the placebo group [66]. These data question the strategy of ACAT inhibition in treating hypercholesterolemia. Our data on the other hand suggests that an increase in SOAT1 expression is key to the formation of cholesterol esters (and reduction in free cholesterol) prior to HDL mediated cellular cholesterol efflux.

In summary, using a series of 1-alkyl-2-acylglycerols, we showed that membrane PlsEtn levels can be selectively restored in a PlsEtn deficient system and selectively augmented in PlsEtn normal cells in a concentration-dependent manner. Accordingly, these results represent the first report of selective plasmalogen enhancement in normal cells. The structure activity relationship study suggests that selective PUFA-PlsEtn enhancement is capable of beneficially favoring cholesterol esterification, an obligate step prior to efflux from the cell. This translates to a net reduction in the fraction of free cholesterol in cells. Plasmalogen restoration/enhancement therefore offers a novel mechanism of cholesterol reduction in vitro.

Competing interests
PLW is CEO of and owns stock in Phreedom Pharma. DBG is CEO of and owns stock in Phenomenome Discoveries Inc.

Authors’ contributions
RM designed and conducted experiments, prepared the manuscript. PWKA and DJ synthesized compounds used in the study. HM carried out experiments. KKS carried out statistical analyses. MAK participated in design of experiments. SR, PLW and DBG participated in design and manuscript preparation. All authors read and approved the manuscript.

Acknowledgements
We thank Dr. R.A. Zoeller for the CHO/NRel-4 cell lines. We are grateful to Saskatchewan Structural Science Centre at the University of Saskatchewan for granting us access to their 500 MHz NMR spectrometer.

Author Details
Phenomenome Discoveries Inc. and Phreedom Pharma, 204-407 Downey Road, Saskatoon, SK, S7N 4L8, Canada

Received: 27 April 2010 Accepted: 14 June 2010
Published: 14 June 2010

References
1. Fielding CJ, Fielding PE: Membrane cholesterol and the regulation of signal transduction. Biochemical Society transactions 2004, 32(Pt 1):55–69.
2. Zwijsen RM, Oudenhoven IM, de Haan LH: Effects of cholesterol and oxysterols on gap junctional communication between human smooth muscle cells. European journal of pharmacology 1992, 228(2-3):115-120.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
4. Fowler SB, Kelly M, Ruh D, Johnson-Wells D: Management of lipid disorders for stroke prevention. J Neurosci Nurs 2006, 38(4 Suppl):282-287. 295
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (New York, NY) 1993, 261(5123):921-923.
6. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Current opinion in clinical nutrition and metabolic care 2006, 9(1):37-38.

7. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Current opinion in lipidology 2001, 12(2):105-112.

8. Muse ED, Jurevics H, Toews AD, Matsushima GK, Morel P. Parameters related to lipid metabolism as markers of myelination in mouse brain. J Neurochem 2001, 76(1):77-86.

9. Martins I, Berger T, Sharmam MJ, Verdle G, Fuller SL, Martins RN. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. J Neurochem 2009, 111(6):1275-1308.

10. Breckenridge WC, Morgan IG, Zanetta JP, Vincendon G. Potential protectors against lipid peroxidation of low density lipoproteins. II. Lipid composition. Biochimica et biophysica acta 1973, 320(3):681-686.

11. Lohner K, Balgavy P, Hermetter A, Paltauf F, Laggner P. Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogens. Biochimica et biophysica acta 1991, 1061(2):132-140.

12. Glaser PE, Gross RW. Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isomerase of glycerolaldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fucosogenic roles of individual isoforms. Biochemistry 1995, 34(38):12193-12203.

13. Brosche T, Platt D. Adult rat brain synaptic vesicles. II. Lipid composition. Biochimica et biophysica acta 1973, 320(3):681-686.

14. Duhm J, Engelmann B, Schonthier UM, Streich S. Accelerated maximal velocity of the red blood cell Na+/K+ pump in hyperlipidemia is positively correlated with high-density lipoprotein and decrease with aging. J of atherosclerosis and thrombosis 2007, 14(1):12-18.

15. Ford DA, Hale CC. Plasma phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochemical and biophysical research communications 1998, 250(2):367-373.

16. Nakayama R, Saito K. Presence of 1-O-alkyl-1'-enyl-2-O-acetyl glycerolipids in perfused rat and guinea pig hearts. J of biochemistry 1989, 105(4):494-496.

17. Choi WH, Olson MS. Platelet-activating factor: receptors and signal transduction. The Biochemical journal 1993, 292(Pt 3):617-629.

18. Engelmann B, Brautigam C, Thierry J. Plasmalogens as potential protectors against lipid peroxidation of low density lipoproteins. Biochemical and biophysical research communications 1994, 204(3):1235-1242.

19. Boscio T, Pizzirani P. The biological significance of plasmalogens in defense against oxidative damage. Experimental gerontology 1998, 33(5):363-369.

20. Kuczynski B, Reo NV. Evidence that plasmalogens are protective against oxidative stress in the rat brain. Neurochemical research 2006, 31(5):659-656.

21. Zoeller RA, Gracia TJ, LaCarrera P, Park J, Gapochkin DP, Farber HW. Increasing plasmalogens levels protects human endothelial cells during hypoxia. American journal of physiology 2002, 283(2):H671-679.

22. Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer’s disease: deficiency of ethanolamine plasmalogens. Neurochemical research 1997, 22(4):523-527.

23. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogens in the brain with Alzheimer disease. Journal of neuropathology and experimental neuropathology 1999, 58(7):740-747.

24. Heymans HS, Schutgens RB, Tan R, van den Bosch H, Borst P. Severe plasmalogens deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983, 306(5939):68-70.

25. Murphy DJ, Schapira MB, Rapoport SI, Shetty HJ. Phospholipid composition and levels are altered in Down syndrome brain. Brain research 2000, 867(1-2):9-18.

26. Schedin S, Sindelar PJ, Pentichev P, Brunk U, Dallner G. Peroxosomal impairment in Niemann-Pick type C disease. The Journal of biological chemistry 1997, 272(10):6245-6251.

27. van den Bosch H, Schrakamp G, Hardeman D, Zomer AW, Wanders RJ, Schutgens RB. Ether lipid synthesis and its deficiency in peroxisomal disorders. Biochimie 1993, 75(3):183-189.

28. Wells K, Farooqui AA, Liss L, Horrocks LA. Neural membrane phospholipids in Alzheimer disease. Neurochemical research 1995, 20(11):1329-1333.

29. Ginsberg L, Rafigue S, Kueber JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain research 1995, 698(1-2):223-226.

30. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrosporionization mass spectrometry. J Neurochem 2001, 77(4):1168-1180.

31. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahihounu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KE, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. Journal of lipid research 2007, 48(11):2485-2498.

32. Stenkvinkel P, Diczfalussy U, Lindholm B, Heibermger O. Phospholipid plasmalogens, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 2004, 19(4):972-976.

33. Goodenowe DB. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. 2008. In, GOIN 33/483 (2006.01) edn. US PCT/CA2008/000659.

34. Horrocks LA, Varroollins M, Yates AJ. The Molecular Basis of NeuroPathology. London, 1981.

35. Maeba R, Maeda T, Kinoshita M, Takaoka K, Takahashi K, Kusano J, Yoshimura N, Takeda Y, Yasuda D, Okazaki T, et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. Journal of atherosclerosis and thrombosis 2007, 14(1):12-18.

36. Engelmann B, Streich S, Schonthier UM, Richter WO, Duhm J. Changes of membrane phospholipid composition of human erythrocytes in hyperlipemia. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochimica et biophysica acta 1992, 1165(4):32-37.

37. Mandel H, Shaf R, Berant M, Wanders RJ, Vreken P, Aviram M. Plasmalogens phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. Biochemical and biological research communications 1998, 250(2):367-373.

38. Munn NJ, Arnoo E, Liu D, Zoeller RA, Liscum L. Deficiency in ethanolamine plasmalogens leads to altered cholesterol transport. Journal of lipid research 2003, 44(1):162-192.

39. Bhattacharjee SC, Hajdu J. Stereoselective synthesis of 2-(R)-1-O-alkylglycerol-3-phosphate and alkyl-acyl analogues: application for synthesis of radiolabelled biosynthetic precursors of cell surface glycoconjugates of Leishmania donovani. J Chem Soc, Perkin Trans 1997, 1:1845-1849.

40. Halliordson A, Thordarson P, Kristinsson B, Magnusson C, Haraldsson GG. Lipase-catalyzed kinetic resolution of 1-O-alkylglycerols by sequential transesterification. Tetrahedron Asymmetry 1998, 9:1845-1849.

41. Yashunsky DV, Borodkin VS, Ferguson MA, Nikolaev AV. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. FEBS letters 1998, 394(1):99-102.

42. Smulski J, Halkier B. Ether lipids and their precursors in normal and pathological membranes. FEBS letters 1998, 436(2):121-125.

43. Jakobson M, Bodnar LA. Ether lipids and their precursors in normal and pathological membranes. FEBS letters 1998, 436(2):121-125.

44. Ramesha CS, Pickett WC, Murthy DV. Meta- and para-alkyl analogues: application for synthesis of radiolabelled biosynthetic precursors of cell surface glycoconjugates of Leishmania donovani. J Chem Soc, Perkin Trans 1997, 1:1845-1849.
47. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. *Toxicology and applied pharmacology* 1997, 145(1):99-110.

48. Muzio G, Martinasso G, Trombettta A, Di Simone D, Canuto RA, Maggiora M. HMG-CoA reductase and PPARalpha are involved in clofibrate-induced apoptosis in human keratinocytes. *Aptosis* 2006, 11(2):265-275.

49. Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP. Inhibition of cell mobility by troglitazone in human ovarian carcinoma cell line. *BMC cancer* 2007, 7:216.

50. Liu D, Nagan N, Just WW, Rodemer C, Thai TP, Zoeller RA. Role of dihydroxyacetonephosphate acyltransferase in the biosynthesis of plasmalogens and nonether glycerolipids. *Journal of lipid research* 2005, 46(4):727-735.

51. Nagan N, Hajra AK, Larkins LK, Lazarow P, Purdue PE, Rizzo WB, Zoeller RA. Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthetic use of a novel two-step selection protocol. *The Biochemical journal* 1998, 332(Pt 1):273-279.

52. Feulgen R, Voit K. Uber einen weiterbreiteten fasten Aldehyd. *Arch Physiol* 1924, 206:217-245.

53. Klenk E, Deubch H. [Information on acetalphosphatides.]. *Hoppe-Seyler's Zeitschrift fur physiologische Chemie* 1954, 296(3-4):179-188.

54. Rapport IM, FraniêRE. The structure of plasmalogens. III. The nature and significance of the aldehydogenic linkage. *J Neurochem* 1957, 14:303-310.

55. Chakravarty BR, Spence MW, Clarke JT, Cook HW. Rapid isolation of neuroblastoma plasma membranes on Percoll gradients. Characterization and lipid composition. *Biochimica et biophysica acta* 1985, 812(1):223-233.

56. Deshmukh DS, Vorbrodt AW, Lee-PK, Bear WD, Kuzzen S. Studies on the submicrosomal fractions of bovine oligodendroglia: lipid composition and glycolipid biosynthesis. *Neurochemical research* 1988, 13(6):571-582.

57. Lange Y, Streibel F, Steck TL. Role of the plasma membrane in cholesterol esterification in rat hepatoma cells. *The Journal of biological chemistry* 1993, 268(19):13838-13843.

58. Spohn M, Davison AN. Cholesterol metabolism in myelin and other subcellular fractions of rat brain. *Journal of lipid research* 1972, 13(5):563-570.

59. Hill SA, McQueen MJ. Reverse cholesterol transport—a review of the process and its clinical implications. *Clinical biochemistry* 1997, 30(7):517-525.

60. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. *Journal of lipid research* 1992, 33(8):1091-1097.

61. Aviram M, Bierman EL, Oram JF. High density lipoprotein stimulates cholesterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. *Journal of lipid research* 1989, 30(1):65-76.

62. Tabas I, Rossow WJ, Boykow GC. Acyl coenzyme A:cholesterol acyl transferase in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. *The Journal of biological chemistry* 1988, 263(3):1266-1272.

63. Holub BJ. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. *Prostaglandins, leukotrienes, and essential fatty acids* 2009, 81(2-3):199-204.

64. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nichols SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. *The New England journal of medicine* 2006, 354(12):1253-1263.

65. Tardif JC, Gregoire J, Laliber FL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassain A, et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. *Circulation* 2004, 110(21):3372-3377.

66. Meuvezé MC, de Groot E, Duivendooen R, Trië MD, Ose L, Martz Fl, Basart DC, Kastelein JJ, Habib R, Davidson MH, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. *Jama* 2009, 301(11):1131-1139.